Summary of Key Information:

Reporting Period: Quarter ended June 30, 2026 (Q1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting

Date of Board Meeting / Approval: August 11, 2026

Audit Opinion: Unmodified limited review report by statutory auditors. No material misstatements found.

Auditor’s Comment: The auditor drew attention to Note 3 regarding the amalgamation accounted for under Ind AS 103 for business combinations under common control, with comparative periods restated. Conclusion not modified.

Key Financial Highlights [₹ in million as per document]

Standalone Results:

  • Revenue from Operations: ₹3,536.90 for Q1 June 2026, compared to ₹3,281.80 in Q1 June 2025 (restated), increase of 7.8% YoY. Compared to ₹3,724.90 in Q4 March 2026, decrease of 5.1% QoQ.
  • Total Income: ₹3,682.80
  • EBITDA: Not Specified
  • Net Profit: ₹209.20, compared to ₹173.00 in Q1 June 2025, increase of 20.9% YoY. Compared to ₹358.10 in Q4 March 2026, decrease of 41.6% QoQ.
  • EPS: Basic ₹0.48, Diluted ₹0.47
  • Other Equity: Not Specified for current period; previous year ended March 2026 was ₹31,017.00
  • Cash and Cash Equivalents: Not Specified
  • Debt: Not Specified

Consolidated Results:

  • Revenue from Operations: ₹9,463.60 for Q1 June 2026, compared to ₹7,916.40 in Q1 June 2025 (restated), increase of 19.5% YoY. Compared to ₹9,199.60 in Q4 March 2026, increase of 2.9% QoQ.
  • Total Income: ₹9,546.70
  • EBITDA: Not Specified
  • Net Profit: ₹792.90, with profit attributable to owners of the Company: ₹658.70, and non-controlling interest: ₹134.20. Compared to Q1 June 2025, profit attributable to owners was ₹318.10, increase of 107% YoY.
  • EPS: Basic ₹1.51, Diluted ₹1.47
  • Other Equity: Not Specified for current period; previous year ended March 2026 was ₹28,236.90
  • Cash and Cash Equivalents: Not Specified
  • Debt: Not Specified

Segment-wise Performance:

Not Specified as there is no separate reportable segment per Ind AS 108.

Corporate Actions:

  • Dividend: Not Declared
  • ESOP Allotment: Allotment of 10,30,775 equity shares of ₹2 each to employees under ESOP Scheme 2026 at an exercise price of ₹101 per share (including premium of ₹99). Paid-up equity share capital increased from ₹87,77,53,626 (43,88,76,813 shares) to ₹87,98,15,176 (43,99,07,588 shares).
  • Rights Issue: Subscription to equity shares of Alivira Animal Health Limited (AAHL), a wholly owned subsidiary, on rights basis for ₹400,02,15,648. The subscription amount will be adjusted against intercompany loans, strengthening AAHL's capital structure and reducing interest burden. No change in shareholding percentage.
  • Incorporation of Subsidiary: Approved incorporation of a wholly owned step-down subsidiary in Vietnam through AAHL or AAHL Ireland. Investment of up to USD 400,000. The subsidiary will engage in importation, registration, marketing, sale, and distribution of animal health products in Vietnam.

Other Significant Information:

  • The Group applied Ind AS 29 for hyperinflation accounting on Turkish subsidiaries.
  • Pending acquisition: Through AAHL Ireland, entered into Sale and Purchase Agreement for acquisition of 100% of BioForlife Italia S.r.l. for EURO 16.976 million, subject to approvals. No impact on current results.
  • Exceptional items for previous periods related to Scheme of Amalgamation expenses, including stamp duty and transaction costs.